139 related articles for article (PubMed ID: 33826473)
21. Melatonin as a Therapeutic Resource for Inflammatory Visual Diseases.
Aranda ML; Fleitas MFG; Dieguez H; Iaquinandi A; Sande PH; Dorfman D; Rosenstein RE
Curr Neuropharmacol; 2017; 15(7):951-962. PubMed ID: 28088912
[TBL] [Abstract][Full Text] [Related]
22. Demographics, treatment patterns, and healthcare utilization and cost of repository corticotropin injection in patients with systemic lupus erythematosus or rheumatoid arthritis.
Wu B; Deshpande G; Gu T; Popelar B; Philbin M; Wan GJ
J Med Econ; 2017 Nov; 20(11):1170-1177. PubMed ID: 28760047
[TBL] [Abstract][Full Text] [Related]
23. Characteristics and management of ocular sarcoidosis.
Takase H
Immunol Med; 2022 Mar; 45(1):12-21. PubMed ID: 34214013
[TBL] [Abstract][Full Text] [Related]
24. Effects of Subcutaneous Repository Corticotropin Gel Injection on Regulatory T Cell Population in Noninfectious Retinal Vasculitis.
Anesi SD; Chang PY; Maleki A; Manhapra A; Look-Why S; Asgari S; Walsh M; Drenen K; Foster CS
Ocul Immunol Inflamm; 2023 Apr; 31(3):556-565. PubMed ID: 35258389
[TBL] [Abstract][Full Text] [Related]
25. Corticosteroid Use and Adherence in Patients Treated with Acthar Gel for Advanced Sarcoidosis.
Hayes K; Niewoehner J; Rice JB; Downes N; Hagopian E; Ma I; Wan GJ
Adv Ther; 2023 Nov; 40(11):4999-5015. PubMed ID: 37728695
[TBL] [Abstract][Full Text] [Related]
26. Multicenter, retrospective, observational study for the Treatment Pattern of systemic corticoSTERoids for relapse of non-infectious uveitis accompanying Vogt-Koyanagi-Harada disease or sarcoidosis.
Namba K; Takase H; Usui Y; Nitta F; Maruyama K; Kusuhara S; Takeuchi M; Azumi A; Yanai R; Kaneko Y; Hasegawa E; Nakai K; Tsuruga H; Morita K; Kaburaki T
Jpn J Ophthalmol; 2022 Mar; 66(2):130-141. PubMed ID: 35044561
[TBL] [Abstract][Full Text] [Related]
27. Response to Acthar Gel in sarcoidosis uveitis: A prospective open label study.
Ungprasert P; Lowder C; Sharma S; Ribeiro Neto ML; Baran J; Srivastava SK; Culver DA
Respir Med; 2023; 219():107422. PubMed ID: 37827293
[TBL] [Abstract][Full Text] [Related]
28. Recommendations for the management of ocular sarcoidosis from the International Workshop on Ocular Sarcoidosis.
Takase H; Acharya NR; Babu K; Bodaghi B; Khairallah M; McCluskey PJ; Tesavibul N; Thorne JE; Tugal-Tutkun I; Yamamoto JH; Rao NA; Smith JR; Mochizuki M
Br J Ophthalmol; 2021 Nov; 105(11):1515-1519. PubMed ID: 32933934
[TBL] [Abstract][Full Text] [Related]
29. Sarcoid Uveitis: An Intriguing Challenger.
Allegri P; Olivari S; Rissotto F; Rissotto R
Medicina (Kaunas); 2022 Jul; 58(7):. PubMed ID: 35888617
[TBL] [Abstract][Full Text] [Related]
30. Cardiac Screening and Disease Characteristics of Patients with Ocular Sarcoidosis.
Van Swol JM; Hawkins ET; Joseph ED; Nguyen SA; Anderson RJ; Thompson EB; Perry LJ; Sandhu HS
Ocul Immunol Inflamm; 2024 Feb; 32(2):148-153. PubMed ID: 36519298
[TBL] [Abstract][Full Text] [Related]
31. [Ocular sarcoidosis].
Springer-Wanner C; Brauns T
Z Rheumatol; 2017 Jun; 76(5):391-397. PubMed ID: 28516270
[TBL] [Abstract][Full Text] [Related]
32. Acthar Gel (repository corticotropin injection) for persistently active SLE: study design and baseline characteristics from a multicentre, randomised, double-blind, placebo-controlled trial.
Askanase AD; Zhao E; Zhu J; Connolly-Strong E; Furie RA
Lupus Sci Med; 2020; 7(1):e000383. PubMed ID: 32399253
[TBL] [Abstract][Full Text] [Related]
33. Outcome of tocilizumab treatment in refractory ocular inflammatory diseases.
Silpa-Archa S; Oray M; Preble JM; Foster CS
Acta Ophthalmol; 2016 Sep; 94(6):e400-6. PubMed ID: 27010181
[TBL] [Abstract][Full Text] [Related]
34. Visual loss in sarcoid-related uveitis.
Lobo A; Barton K; Minassian D; du Bois RM; Lightman S
Clin Exp Ophthalmol; 2003 Aug; 31(4):310-6. PubMed ID: 12880455
[TBL] [Abstract][Full Text] [Related]
35. Clinical features and visual outcomes of ocular sarcoidosis at a tertiary referral center in Tokyo.
Nagahori K; Keino H; Nakayama M; Watanabe T; Ando Y; Hayashi I; Abe S; Okada AA
Graefes Arch Clin Exp Ophthalmol; 2022 Oct; 260(10):3357-3363. PubMed ID: 35616725
[TBL] [Abstract][Full Text] [Related]
36. Follow-up results of myositis patients treated with H. P. Acthar gel.
Saygin D; Oddis CV; Marder G; Moghadam-Kia S; Nandkumar P; Neiman N; Dzanko S; Koontz D; Aggarwal R
Rheumatology (Oxford); 2020 Oct; 59(10):2976-2981. PubMed ID: 32160301
[TBL] [Abstract][Full Text] [Related]
37. Repository Corticotropin Injection (Acthar
Wirta D; McLaurin E; Ousler G; Liu J; Kacmaz RO; Grieco J
Ophthalmol Ther; 2021 Dec; 10(4):1077-1092. PubMed ID: 34669183
[TBL] [Abstract][Full Text] [Related]
38. Repository corticotropin injection versus corticosteroids for protection against renal damage in a focal segmental glomerulosclerosis rodent model.
Hayes K; Warner E; Bollinger C; Wright D; Fitch RM
BMC Nephrol; 2020 Jun; 21(1):226. PubMed ID: 32539845
[TBL] [Abstract][Full Text] [Related]
39. Cyclophosphamide for ocular inflammatory diseases.
Pujari SS; Kempen JH; Newcomb CW; Gangaputra S; Daniel E; Suhler EB; Thorne JE; Jabs DA; Levy-Clarke GA; Nussenblatt RB; Rosenbaum JT; Foster CS
Ophthalmology; 2010 Feb; 117(2):356-65. PubMed ID: 19969366
[TBL] [Abstract][Full Text] [Related]
40. Real-world treatment patterns for repository corticotropin injection in patients with rheumatoid arthritis.
Busch H; Wan GJ; Niewoehner J; Houston P; Su Y; Clinton C; Panaccio MP
Drugs Context; 2022; 11():. PubMed ID: 35382109
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
